Intercept Pharmaceuticals, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
HZNPHorizon Therapeutics Plc 1.38%73.415.8%$206.83m
VRXValeant Pharmaceuticals International, Inc. 0.67%17.3114.1%$101.85m
BHCBausch Health Cos., Inc. 0.58%17.290.0%$79.82m
JAZZJazz Pharmaceuticals Plc 1.10%124.472.4%$77.68m
CTLTCatalent, Inc. -1.47%87.122.2%$75.27m
PRGOPerrigo Co. Plc 1.27%53.306.8%$49.50m
TNXPTonix Pharmaceuticals Holding Corp. -10.53%1.020.5%$48.91m
GWPHGW Pharmaceuticals Plc -1.55%106.806.2%$43.85m
ARGXargenx SE -1.45%233.960.0%$43.64m
ICPTIntercept Pharmaceuticals, Inc. -3.88%49.8516.8%$43.03m
PCRXPacira Biosciences, Inc. 0.82%61.1810.2%$40.87m
AMRNAmarin Corp. Plc 0.59%6.801.5%$40.28m
ICLRICON plc -1.94%188.404.3%$40.27m
MYOKMyoKardia, Inc. -1.36%100.291.8%$38.35m
VRNAVerona Pharma Plc 10.17%7.910.0%$37.53m

Company Profile

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.